A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

Kim Papp; Stephen K. Tyring; M. Lahfa; Jörg C. Prinz; Christopher Em Griffiths; Arline Nakanishi; Ralph Zitnik; P.C.M. van de Kerkhof

doi:10.1111/j.1365-2133.2005.06688.x

Abstract

1 min read

Etanercept provided clinically meaningful benefit to patients with chronic plaque psoriasis, with no apparent decrease in efficacy after dose reduction.

Related publications

Article2005

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial

Gerald G. Krueger, Richard G. Langley, A.Y. Finlay, Christopher Em Griffiths, J. Michael Woolley, Deepa Lalla, Angelika Jahreis

Article2008

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

Sakari Reitamo, Phyllis I. Spuls, B. Sassolas, Morad Lahfa, A Claudy, Christopher Em Griffiths

Article2008

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

Jean‐Paul Ortonne, Christopher Em Griffiths, E. Daudén, Robert Strohal, Deborah Robertson, Ronald Pedersen, C. Molta, Bruce Freundlich

Article2010

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

Christopher Em Griffiths, Bruce Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, B. Zhou, Shu Li, Lisa T. Dooley, Neil Goldstein, Alan Menter

Article2017

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt, Kim Papp, Christopher Em Griffiths, L. Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin